What percentage of patients aged 65 years and older with early symptomatic Alzheimer’s disease receiving Kisunla (donanemab) develop amyloid‑related imaging abnormalities (ARIA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ARIA Incidence with Kisunla (Donanemab)

Up to 29% of patients on Kisunla develop ARIA (any type), with ARIA-E occurring in approximately 16-24% and ARIA-H in 25-31% of patients, depending on the dosing regimen used. 1

Breakdown by ARIA Type and Dosing Regimen

Dosing Regimen 2 (Recommended Dosage)

  • Total ARIA: 29% of patients
  • ARIA-E (edema/effusion): 16% of patients
  • ARIA-H (hemorrhage): 25% of patients
  • Symptomatic ARIA-E: 3% of patients 1

Dosing Regimen 1 (Higher Incidence)

  • Total ARIA: 36% of patients
  • ARIA-E: 24% of patients
  • ARIA-H: 31% of patients
  • Symptomatic ARIA-E: 6% of patients 1

The recommended Dosing Regimen 2 was specifically selected because it demonstrates lower ARIA-E rates compared to Dosing Regimen 1, making it the safer option for clinical use 1.

Clinical Context from Guidelines

The 2025 ACR Appropriateness Criteria confirms these rates, noting that ARIA-E was detected in up to 26.7% of patients undergoing therapy with donanemab in the TRAILBLAZER-ALZ phase 2 and phase 3 trials 2. This aligns closely with the FDA label data, providing consistent evidence across sources.

For comparison, ARIA-E rates with other anti-amyloid monoclonal antibodies are:

  • Aducanumab: 35-36%
  • Lecanemab: 12.6% 2

Risk Stratification by ApoE ε4 Status

ARIA risk varies substantially based on ApoE ε4 genotype 1:

Study 1 (Dosing Regimen 1) - 18 months:

  • ApoE ε4 homozygotes (ε4/ε4): 55% developed ARIA
    • Symptomatic ARIA-E: 8%
    • Serious ARIA: 3%
  • ApoE ε4 heterozygotes: 36% developed ARIA
    • Symptomatic ARIA-E: 7%
    • Serious ARIA: 2%
  • ApoE ε4 noncarriers: 25% developed ARIA
    • Symptomatic ARIA-E: 4%
    • Serious ARIA: 1%

Study 2 (Dosing Regimen 2) - 12 months:

  • ApoE ε4 homozygotes: 0% symptomatic ARIA-E (limited sample size)
  • ApoE ε4 heterozygotes: 4% symptomatic ARIA-E
  • ApoE ε4 noncarriers: 3% symptomatic ARIA-E 1

ApoE ε4 homozygotes represent approximately 15-17% of Alzheimer's disease patients but carry the highest ARIA risk. Testing for ApoE ε4 status should be performed prior to treatment initiation to inform risk assessment, though treatment can proceed without testing if patients accept the inability to stratify their individual risk 1.

Timing and Severity

ARIA-E typically occurs early in treatment: In 58.3% of donanemab-treated participants who developed ARIA-E, the first event occurred by the third infusion (approximately month 3) 3. This early timing pattern underscores the critical importance of intensive MRI monitoring during the initial treatment phase.

Most ARIA-E is mild to moderate in severity, but serious ARIA-E occurred in 1.5% of patients in placebo-controlled trials 1. Approximately 85% of patients with symptomatic ARIA-E had resolution of clinical symptoms in Study 1, though this decreased to 67% at 12 months in Study 2 1.

Additional Risk Factors Beyond ApoE ε4

Independent risk factors for ARIA-E include 3:

  • Baseline microhemorrhages (≥2 increases risk)
  • Cortical superficial siderosis (≥1 area increases risk)
  • Higher baseline amyloid plaque burden
  • Elevated mean arterial pressure
  • Decreased risk with antihypertensive use

Critical Safety Considerations

Intracerebral hemorrhage >1 cm occurred in 0.5-1% of patients treated with Kisunla 1. Fatal events of intracerebral hemorrhage have been observed, and three deaths in clinical trials were considered treatment-related 4.

Mandatory MRI monitoring is required with sequences including DWI, T2 FLAIR, and T2* GRE or SWI to detect ARIA, as it cannot be reliably detected on CT 2, 1. Regular monitoring should occur before specified infusions, with additional imaging if clinical symptoms develop (headache, confusion, visual changes, dizziness, nausea, gait difficulty, or focal neurologic deficits) 2, 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.